cendoc bogani publicaciones PMD conductas adictivas

Ficha Bibliografía científica

Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study

Ling, Walter; Nadipelli, Vijay R.; Solem, Caitlyn T.; Ronquest, Naoko A.; Yeh, Yu-Chen; Learned, Susan M.; Mehra, Vishaal; Heidbreder, Christian

Año: 2020

Introduction: The physical, social, psychological, and economic burden of opioid use disorder (OUD) is substantial. As of the year 2019, the predominant focus of OUD research was outcomes such as retention and abstinence. We report herein the effects of extended-release buprenorphine (BUP-XR), the first FDA-approved subcutaneously injected, monthly treatment for OUD, on patient-centered outcomes. Materials and methods: Patient-centered outcomes were collected during an open-label safety study of participants with OUD (NCT# 02510014) evaluating BUP-XR. Measures collected during the study included the EQ-5D-5L, SF-36v2, Treatment Effectiveness Assessment (TEA), Addiction Severity Index-Lite (ASI-Lite), employment/insurance status questionnaire, and Medication Satisfaction Questionnaire (MSQ). Changes from baseline to end of study week 49 were analyzed using mixed models for repeated measures. "Baseline" was defined as the value collected prior to the first BUP-XR injection. Results presented are for those participants who initiated treatment on BUP-XR during the open-label study and were eligible to receive up to 12 injections. Results: Four hundred twelve participants were included in analyses; 206 participants discontinued BUP-XR prematurely. Mean EQ-5D-5L scores remained stable from baseline to end of study. Statistically significant improvements from baseline to end of study were noted for the SF-36v2 mental component summary score (difference = 5.0, 95%CI: 3.5-6.5) and 7 of 8 domain scores (P < .05 for all comparisons); the SF-36v2 physical component summary remained stable from baseline to end of study. The TEA total score (difference = 9.3 points, 95%CI: 8.0-10.5) and 4 of 4 domain scores (difference = 2-3 points per domain) significantly improved from baseline to end of study. Significant improvements (P < .05 for all comparisons) on the ASI-Lite were seen for all problem areas except alcohol use from baseline to end of study. Employment rate increased 7% whereas health insurance status remained stable from baseline to end of study. Medication satisfaction measured using the MSQ was > 88% at end of study. Conclusions: Treatment with BUP-XR monthly injections for up to 12 months in this cohort of treatment-seeking individuals with OUD led to positive PCOs and high treatment satisfaction, which correspond to personal recovery.

Tipo documento:

Artículo

Número/Volumen:

110

Páginas:

1-8

Fuente:

JOURNAL OF SUBSTANCE ABUSE TREATMENT

Palabras clave:

Opioid use disorder; Buprenorphine; Patient-centered outcomes; Patient satisfaction; Employment

 

Comparte con otras personas

Compartir Compartir  Compartir

Concejalía de Servicios Sociales de l´Ajuntament de València

Logotipo Universitat de València
Logotipo UISYS
Logotipo CSIC
Logotipo Consellería de Sanitat de la Generalitat Valenciana

Siguenos en:

 

Última actualización: 28/03/2024

Centro de documentación sobre drogodependencias y otros trastornos adictivos Dr. Emilio Bogani Miquel
Cendoc Bogani

Publicaciones, Artículos, Carteles, Posters y enlaces Web sobre Drogodependencias y Trastornos Adictivos relevantes para profesionales de las Ciencias de la Salud, Educación e Información.

Copyright © Centro de documentación sobre drogodependencias y otros trastornos adictivos Dr. Emilio Bogani Miquel, 2019.
Cendoc Bogani - C/ Amadeo de Saboya, 11 - bajo - 46010 - Valencia
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y con fines estadísticos. Al continuar con la navegación entendemos que se acepta nuestra política de cookies. Más Información